biostage, inc. (otcqb: bstg) is a pioneering biotechnology company developing bioengineered organ implants to address unmet needs in the treatment of life-threatening cancer, traumas and congenital abnormalities of the esophagus, bronchus and trachea. the company’s cellframe™ technology platform is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. combining a synthetic scaffold with tissue engineering and cell biology, biostage’s cellframe™ platform is used to create organ specific cellspan™ implants. the cellspan™ implant is delivered directly to the site where tissue regeneration is needed, and has been designed to promote in situ tissue regeneration by providing both stem cell-derived biological signals, and three-dimensional guidance and support for cell growth differentiation. recent large animal data delivered promising results as cellframe™-based cellspan™ implants applied to the esophagus achieved regener
Company profile
Ticker
HRGN
Exchange
Website
CEO
James J. McGorry
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Biostage, Inc.
SEC CIK
Corporate docs
Subsidiaries
Harvard Apparatus Regenerative Technology Limited • Harvard Apparatus Regenerative Technology GmbH ...
IRS number
455210462
HRGN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
17 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Feb 24
S-8
Registration of securities for employees
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 Jul 23
8-K/A
Unregistered Sales of Equity Securities
10 Jul 23
DEFR14A
Revised proxy
7 Jun 23
Transcripts
HRGN
Earnings call transcript
2022 Q3
15 Nov 22
HRGN
Earnings call transcript
2022 Q1
17 May 22
HRGN
Earnings call transcript
2019 Q2
12 Nov 19
HRGN
Earnings call transcript
2019 Q2
13 Aug 19
HRGN
Earnings call transcript
2019 Q1
14 May 19
HRGN
Earnings call transcript
2018 Q4
28 Mar 19
HRGN
Earnings call transcript
2018 Q3
11 Nov 18
HRGN
Earnings call transcript
2018 Q2
14 Aug 18
HRGN
Earnings call transcript
2018 Q1
13 May 18
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 269.00 k | 269.00 k | 269.00 k | 269.00 k | 269.00 k | 269.00 k |
Cash burn (monthly) | 623.67 k | 225.17 k | 541.33 k | 721.25 k | 1.05 mm | 621.17 k |
Cash used (since last report) | 4.24 mm | 1.53 mm | 3.68 mm | 4.90 mm | 7.17 mm | 4.22 mm |
Cash remaining | -3.97 mm | -1.26 mm | -3.41 mm | -4.63 mm | -6.90 mm | -3.95 mm |
Runway (months of cash) | -6.4 | -5.6 | -6.3 | -6.4 | -6.5 | -6.4 |
Institutional ownership, Q4 2022
31.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 14.32 mm |
Total shares | 4.36 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
DST Capital | 3.65 mm | $10.95 mm |
HBIO Harvard Bioscience | 708.52 k | $3.37 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jan 24 | He Junli | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 4.07 | 220,640 | 898.00 k | 220,640 |
27 Dec 23 | He Junli | Common Stock | Buy | Acquire P | No | No | 4.76 | 2,700 | 12.85 k | 253,000 |
14 Dec 23 | He Junli | Common Stock | Buy | Acquire P | No | No | 4.92 | 900 | 4.43 k | 250,300 |
6 Dec 23 | He Junli | Common Stock | Buy | Acquire P | No | No | 5.07 | 1,500 | 7.61 k | 249,400 |
11 Sep 23 | He Junli | Common Stock | Buy | Acquire P | No | No | 5.43 | 1,500 | 8.15 k | 247,900 |